Pearl Therapeutics Announces Positive Results From Phase 2a Trial Of Formoterol Inhalation Aerosol In Chronic Obstructive Pulmonary Disease

Pearl Therapeutics Inc., a company developing high-quality combination therapies for the treatment of highly prevalent chronic respiratory diseases, announced positive results from its first clinical trial in patients with chronic obstructive pulmonary disease (COPD)…

More: continued here

Filed under: Clinical Trials on January 5th, 2010